Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||EML4 - ALK ALK S1206F|
|Gene Variant Detail|
|Relevant Treatment Approaches||Brigatinib|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|EML4 - ALK ALK S1206F||Advanced Solid Tumor||sensitive||Brigatinib||Brigatinib||Preclinical - Cell culture||Actionable||In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK S1206F in the context of EML4-ALK in culture (PMID: 27780853).||27780853|
|EML4 - ALK ALK S1206F||lung adenocarcinoma||predicted - sensitive||Crizotinib||Case Reports/Case Series||Actionable||In a clinical case study, Xalkori (crizotinib) treatment resulted in clinical improvement within one week of therapy, a 30.3% decrease in target lesion and a partial response after 2 months, and an ongoing response after 4 months in a patient with lung adenocarcinoma harboring de novo EML4-ALK-(E5;A20) and ALK S1206F (PMID: 27565908).||27565908|